Search

everythinglearnresearchcommunity

for

Search:↓

People are discussing ketoconazole shampoos that don't dry out hair, with suggestions including using it as a topical treatment, switching to T-Sal, and using moisturizing products like hyaluronic acid serum and biotin conditioner. Regenepure DR is confirmed to still contain ketoconazole, and some users recommend using moisturizing shampoos and conditioners to prevent dryness.

The user is frustrated with the delayed delivery of their Pryiltamide order from Koshine. They mention the order was shipped on August 23 but have received no updates since.

Mixing charcoal, Ketoconazole, and caffeinated shampoo is questioned for potential interaction, specifically if charcoal inactivates other ingredients. Charcoal is used for seborrheic dermatitis, while caffeine is thought to improve scalp blood flow.

People are discussing their experiences with kx-826 (pyrilutamide) for hair loss, using concentrations of 0.5% and 0.9%. They are sharing personal results and progress with this treatment.

Kintor 0.9% is not effective for hair regrowth or thickening and may cause testicle sensitivity. The conversation criticizes the hype around Kintor and discusses the ineffectiveness of pyrilutamide compared to other treatments like RU58841, finasteride, and minoxidil.

PP405 shows promise for hair growth with significant results after 4 weeks, but skepticism exists due to its unavailability. Some users are hopeful for its potential, while others express concerns about side effects and market release delays.

Reducing the dose of Pyrilutamide from 5mg to 2.5mg may still maintain hair loss results, but effectiveness can vary. Users discuss the cost and dosage implications, with some cautioning against reducing the dose due to its dose-dependent nature.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

The user is exploring KX-826 as a potential hair loss treatment due to intolerance to FDA-approved drugs like Minoxidil and finasteride. They seek fundamental help and information about KX-826.

The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.

KX-826 shows promise for hair maintenance at higher doses with minimal side effects, despite failing Phase III trials. The user believes it is more effective than Minoxidil, Finasteride, and RU58841.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

Minokem-N's composition is unclear, with concerns about unlisted hydrocortisone. Users discuss alternatives like AloATM, which lacks soothing agents, and the challenges of verifying ingredients.

Breezula (cb-03-01) and kx-826 are discussed as hair loss treatments. Kx-826 is available on Kintor's website, while Breezula is available on the grey market.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

The conversation is about finding a clinic in the UK or USA that provides topical finasteride 0.02% or KX-826 for hair loss treatment. Users discuss alternatives like mixing finasteride pills with minoxidil and mention the availability of KX-826 on Amazon.

The conversation is about using finasteride and KX826 for hair loss treatment. The original poster is using 0.25 mg of finasteride every other day due to side effects at a higher dose.

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

The user added P5P (vitamin B6) to their shampoo to reduce scalp itch, which improved significantly. They have been using finasteride for hair loss but are exploring additional treatments like topical antiandrogens and prolactin inhibitors.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.

Imidazole drugs like ketoconazole inhibit certain enzymes and prevent DHT from binding to SHBG, increasing free DHT in the bloodstream, which may contribute to balding. The discussion questions how these drugs help with hair loss despite this effect.

The conversation discusses the sale of a premixed KY19382 solution for research purposes, highlighting previous unsuccessful group buys and the formulation process. Prices and purchasing options for KY19382 solutions and powder are provided.

The conversation discusses various hair loss treatments, including Breezula, KX826, and PP405, with mixed opinions on their effectiveness compared to finasteride and minoxidil. Some users express skepticism about the new treatments, while others remain hopeful about future developments.

Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

The conversation discusses using a violet ray device for hair regrowth, citing a case where zinc ion treatments showed promising results. It also mentions similar devices like the Growcombr and niostem helmet.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

KOSHINE826 is a new anti-hair loss and hair growth solution that claims to effectively control oil, reduce hair fall, and promote real hair growth. It targets androgenetic alopecia by inhibiting DHT and has shown promising results in clinical trials.